CN112088164A - 表达膜结合IL-10的遗传重编程的Treg - Google Patents

表达膜结合IL-10的遗传重编程的Treg Download PDF

Info

Publication number
CN112088164A
CN112088164A CN201980021334.8A CN201980021334A CN112088164A CN 112088164 A CN112088164 A CN 112088164A CN 201980021334 A CN201980021334 A CN 201980021334A CN 112088164 A CN112088164 A CN 112088164A
Authority
CN
China
Prior art keywords
ser
gly
leu
nucleic acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980021334.8A
Other languages
English (en)
Chinese (zh)
Inventor
G·格罗斯
H·温斯坦-马罗姆
A·克罗纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gavish-Galilee Bio Applications Ltd
Original Assignee
Gavish-Galilee Bio Applications Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gavish-Galilee Bio Applications Ltd filed Critical Gavish-Galilee Bio Applications Ltd
Publication of CN112088164A publication Critical patent/CN112088164A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
CN201980021334.8A 2018-03-23 2019-03-22 表达膜结合IL-10的遗传重编程的Treg Pending CN112088164A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647084P 2018-03-23 2018-03-23
US62/647,084 2018-03-23
PCT/IL2019/050324 WO2019180724A1 (en) 2018-03-23 2019-03-22 Genetically reprogrammed tregs expressing membrane-bound il-10

Publications (1)

Publication Number Publication Date
CN112088164A true CN112088164A (zh) 2020-12-15

Family

ID=66448601

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980021334.8A Pending CN112088164A (zh) 2018-03-23 2019-03-22 表达膜结合IL-10的遗传重编程的Treg

Country Status (10)

Country Link
US (1) US20210347843A9 (https=)
EP (1) EP3768699B1 (https=)
JP (2) JP7404331B2 (https=)
KR (1) KR102943105B1 (https=)
CN (1) CN112088164A (https=)
AU (1) AU2019240370B2 (https=)
CA (1) CA3094927A1 (https=)
IL (1) IL277541A (https=)
SG (1) SG11202010454PA (https=)
WO (1) WO2019180724A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119331826A (zh) * 2024-12-18 2025-01-21 智在汉青生物科技(浙江)有限公司 用于增强细胞免疫疗法的表达非分泌型il-10的免疫细胞、制备方法及用途
WO2025148750A1 (zh) * 2024-01-08 2025-07-17 上药生物治疗（香港）有限公司 膜表达il-10及其用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220186232A1 (en) * 2019-03-26 2022-06-16 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed tregs expressing cars
EP4536689A1 (en) * 2022-06-10 2025-04-16 Medizinische Hochschule Hannover Fusion protein for maintenance of regulatory t-cells
EP4289859A1 (en) * 2022-06-10 2023-12-13 Medizinische Hochschule Hannover Fusion protein for maintenance of regulatory t-cells
EP4565702A1 (en) * 2022-08-03 2025-06-11 Migal Galilee Research Institute Ltd. Chimeric membrane-bound cytokines incorporating costimulatory elements for enhancing anti-inflammatory function

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005010215A2 (en) * 2003-07-17 2005-02-03 Tolerrx, Inc. Methods for identifying tolerance modulatory compounds and uses therefor
AU2013203561A1 (en) * 2009-05-15 2013-05-02 Irx Therapeutics, Inc. Vaccine immunotherapy
AU2012233652A1 (en) * 2011-03-31 2013-10-24 Centre Leon Berard Antibodies directed against ICOS and uses thereof
WO2017123557A1 (en) * 2016-01-11 2017-07-20 Armo Biosciences, Inc. Interleukin-10 in production of antigen-specific cd8+ t cells and methods of use of same
CN107216395A (zh) * 2017-07-03 2017-09-29 上海科医联创生物科技有限公司 一种tm4sf1特异性嵌合抗原受体及其应用
CN107614519A (zh) * 2015-10-23 2018-01-19 优瑞科生物技术公司 抗体/t细胞受体嵌合构建体及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5275100A (en) * 1999-05-21 2000-12-12 Regents Of The University Of California, The Fluorescent protein indicators
WO2001089286A2 (en) * 2000-05-24 2001-11-29 Cel-Sci Corporation T cell binding ligand peptides, peptide constructs containing same and use thereof for treatment of immunological disorders
AU2003241127A1 (en) * 2002-06-12 2003-12-31 Gavish-Galilee Bio Applications Ltd MEMBRANE-ANCHORED Beta2 MICROGLOBULIN COVALENTLY LINKED TO MHC CLASS I PEPTIDE EPITOPES
DE10347710B4 (de) * 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
EP2126054B1 (en) * 2007-01-31 2016-07-06 Yeda Research And Development Company Limited Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
CA2739608A1 (en) * 2008-10-07 2010-04-15 The Regents Of The University Of California Recombinant nell protein production
EP2457579A1 (en) * 2010-11-26 2012-05-30 Technische Universität Dresden Covalently linked interleukin -10
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
MY210545A (en) * 2016-04-01 2025-09-30 Kite Pharma Inc Chimeric receptors to flt3 and methods of use thereof
JP7084881B2 (ja) * 2016-06-22 2022-06-15 アルカームス インコーポレーテッド Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005010215A2 (en) * 2003-07-17 2005-02-03 Tolerrx, Inc. Methods for identifying tolerance modulatory compounds and uses therefor
AU2013203561A1 (en) * 2009-05-15 2013-05-02 Irx Therapeutics, Inc. Vaccine immunotherapy
AU2012233652A1 (en) * 2011-03-31 2013-10-24 Centre Leon Berard Antibodies directed against ICOS and uses thereof
CN107614519A (zh) * 2015-10-23 2018-01-19 优瑞科生物技术公司 抗体/t细胞受体嵌合构建体及其用途
WO2017123557A1 (en) * 2016-01-11 2017-07-20 Armo Biosciences, Inc. Interleukin-10 in production of antigen-specific cd8+ t cells and methods of use of same
CN107216395A (zh) * 2017-07-03 2017-09-29 上海科医联创生物科技有限公司 一种tm4sf1特异性嵌合抗原受体及其应用

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
FUJIO K等: "The Family of IL-10-secreting CD4+ T cells", ADV IMMUNOL, no. 105, pages 99 - 130, XP009192122 *
GRAZIA ANDOLFI等: "Enforced IL-10 Expression Confers Type 1 Regulatory T Cell (Tr1) Phenotype and Function to Human CD4+T Cells", MOLECULAR THERAPY, vol. 20, no. 09, pages 1778 - 1790, XP055592834, DOI: 10.1038/mt.2012.71 *
JETHWA H等: "Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: is now the right time?", CLIN IMMUNOL, vol. 150, no. 01, pages 51 - 63, XP028671363, DOI: 10.1016/j.clim.2013.11.004 *
LOCAFARO G等: "IL-10-Engineered Human CD4+ Tr1 Cells Eliminate Myeloid Leukemia in an HLA Class I-Dependent Mechanism", MOL THER, vol. 25, no. 10, pages 2254 - 2269, XP055592839, DOI: 10.1016/j.ymthe.2017.06.029 *
佚名: "CDQ51648.1", GENBANK, pages 1 - 2 *
佚名: "P_000563.1", GENBANK, pages 1 - 2 *
佚名: "XP_008975953.1", GENBANK, pages 1 *
曾冬竹等: "IL-2和IL-10对Treg细胞体外扩增影响的差异研究", 第三军医大学学报, vol. 267, no. 04, pages 290 - 292 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025148750A1 (zh) * 2024-01-08 2025-07-17 上药生物治疗（香港）有限公司 膜表达il-10及其用途
CN119331826A (zh) * 2024-12-18 2025-01-21 智在汉青生物科技(浙江)有限公司 用于增强细胞免疫疗法的表达非分泌型il-10的免疫细胞、制备方法及用途

Also Published As

Publication number Publication date
EP3768699A1 (en) 2021-01-27
IL277541A (en) 2020-11-30
JP2024019533A (ja) 2024-02-09
WO2019180724A1 (en) 2019-09-26
US20210040169A1 (en) 2021-02-11
US20210347843A9 (en) 2021-11-11
JP2021519107A (ja) 2021-08-10
EP3768699B1 (en) 2025-11-12
AU2019240370B2 (en) 2024-03-07
SG11202010454PA (en) 2020-11-27
KR20210005602A (ko) 2021-01-14
AU2019240370A1 (en) 2020-11-19
CA3094927A1 (en) 2019-09-26
JP7404331B2 (ja) 2023-12-25
KR102943105B1 (ko) 2026-03-24

Similar Documents

Publication Publication Date Title
JP6612963B2 (ja) 腫瘍抗原を直接認識するために組換えｔ細胞レセプターを使用するための組成物及び方法
AU2019240370B2 (en) Genetically reprogrammed Tregs expressing membrane-bound IL-10
TWI835730B (zh) Ｔｃｒ及肽
AU2016342560B2 (en) Receptor
US20220169699A1 (en) Pd-1-cd28 fusion proteins and their use in medicine
KR102276888B1 (ko) 증강된 친화성 t　세포 수용체 및 이의 제조 방법
US20220119477A1 (en) Tcr and peptides
Matsuzaki et al. A rare population of tumor antigen-specific CD4+ CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells
WO2023133540A1 (en) Il-12 affinity variants
TW202146431A (zh) 用於經工程化細胞之嵌合受體
CN111875712A (zh) 一种增强型靶向muc1的嵌合抗原受体及其应用
JP6425301B2 (ja) Ｔｃｒの細胞傷害活性誘導能を評価するためのｎｋ細胞株、およびその作製方法
CN111171156A (zh) 一种识别afp抗原短肽的t细胞受体及其编码序列
HK40042137A (en) Genetically reprogrammed tregs expressing membrane-bound il-10
US20260028388A1 (en) Recombinant cytokine receptors and methods of use
US20250333697A1 (en) Tethered interleukin-2 recombinant receptors and methods of use
CN115820697B (zh) 一种免疫细胞及其制备方法和应用
CN121586727A (zh) 组成型细胞因子受体
HK40058915A (en) Tcr and peptides
HK40024455A (en) Tcr and peptides

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40042137

Country of ref document: HK